Microwave vs radiofrequency ablation for small renal masses: perioperative and oncological outcomes.
TRIFECTA
local recurrence
microwave ablation
operative time
radiofrequency ablation
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
18
9
2024
Statut:
aheadofprint
Résumé
To conduct a comprehensive comparison of microwave ablation (MWA) vs radiofrequency ablation (RFA) outcomes in the treatment of small renal masses (SRMs), specifically: TRIFECTA ([i] complete ablation, [ii] absence of Clavien-Dindo Grade ≥III complications, and [iii] absence of ≥30% decrease in estimated glomerular filtration rate) achievement, operative time (OT), and local recurrence rate (LRR). We retrospectively analysed 531 patients with SRMs (clinical T1a-b) treated with MWA or RFA at a single centre (2008-2022). First, multivariable logistic regression models were used for testing TRIFECTA achievement. Second, multivariable Poisson regression models were used to evaluate variables associated with longer OT. Finally, Kaplan-Meier plots depicted LRR over time. All analyses were repeated after 1:1 propensity score matching (PSM). Of 531 patients with SRMs, 373/531 (70.2%) underwent MWA and 158/531 (29.8%) RFA. MWA demonstrated superior TRIFECTA achievement (314/373 [84.2%]) compared to RFA (114/158 [72.2%], P = 0.001). These differences were driven by higher rates of complete ablation in MWA- vs RFA-treated patients (348/373 [93.3%] vs 137/158 [86.7%], P < 0.001). In multivariable logistic regression models, MWA was associated with higher TRIFECTA achievement, compared to RFA, before (odds ratio [OR] 1.92, P = 0.008) and after PSM (OR 1.99, P = 0.023). Finally, the median OT was shorter for MWA vs RFA (105 vs 115 min; P = 0.002). At Poisson regression analyses, MWA predicted shorter OT before (incidence rate ratio [IRR] 0.86, P < 0.001) and after PSM (IRR 0.85, P < 0.001). Local recurrence occurred in 17/373 (4.6%) MWA-treated patients and 21/158 (13.3%) RFA-treated patients (P = 0.29) after a median (interquartile range) follow-up of 24 (8-46) months. There were no differences in the LRR in Kaplan-Meier plots before (P = 0.29) and after PSM (P = 0.42). Microwave ablation provides higher TRIFECTA achievement, and shorter OT than RFA. No significant differences were found regarding the LRR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 BJU International.
Références
Luzzago S, Palumbo C, Rosiello G et al. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non‐clear cell histology: a contemporary population‐based analysis. Urol Oncol 2020; 38: 506–514
Ljungberg B, Bensalah K, Canfield S et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015; 67: 913–924
Campbell SC, Novick AC, Belldegrun A et al. Guideline for management of the clinical T1 renal mass. J Urol 2009; 182: 1271–1279
Escudier B, Porta C, Schmidinger M et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up††approved by the ESMO guidelines committee: September 2008, last update January 2019. This publication supersedes the previously published version—Ann Oncol 201. Ann Oncol 2019; 30: 706–720
Morris CS, Baerlocher MO, Dariushnia SR et al. Society of Interventional Radiology Position Statement on the role of percutaneous ablation in renal cell carcinoma: endorsed by the Canadian Association for Interventional Radiology and the Society of Interventional Oncology. J Vasc Interv Radiol 2020; 31: 189–194.e3
Mauri G, Mistretta FA, Bonomo G et al. Long‐term follow‐up outcomes after percutaneous US/CT‐guided radiofrequency ablation for cT1a‐b renal masses: experience from single high‐volume referral center. Cancer 2020; 12: 1183
Mauri G, Nicosia L, Varano GM et al. Tips and tricks for a safe and effective image‐guided percutaneous renal tumour ablation. Insights Imaging 2017; 8: 357–363
Mauri G, Monfardini L, Della Vigna P et al. Real‐time US‐CT fusion imaging for guidance of thermal ablation in of renal tumors invisible or poorly visible with US: results in 97 cases. Int J Hyperthermia 2021; 38: 771–776
Luzzago S, Mistretta FA, Mauri G et al. Thermal ablation for small renal masses: identifying the most appropriate tumor size cut‐off for predicting perioperative and oncological outcomes. Urol Oncol Semin Orig Investig 2022; 40: 537.e1–537.e9
Musi G, Luzzago S, Mauri G et al. Predicting peri‐operative outcomes in patients treated with percutaneous thermal ablation for small renal masses: the SuNS nephrometry score. Diagnostics 2023; 13: 2955
Clavien PA, Barkun J, de Oliveira ML et al. The clavien‐dindo classification of surgical complications: five‐year experience. Ann Surg 2009; 250: 187–196
Ahmed M, Solbiati L, Brace CL et al. Image‐guided tumorablation: standardization ofterminology and reporting criteria‐a 10‐year update. J Vasc Interv Radiol 2014; 25: 1691–1705.e4
Pazeto CL, Macek P, Amaral B et al. Optimal surgical outcome of minimally invasive partial nephrectomy (MIPN) based on an early postoperative estimated glomerular filtration rate (eGFR). Curr Urol Rep 2021; 22: 36
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383
Kutikov A, Uzzo RG. The R.E.N.A.L. Nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009; 182: 844–853
R: The R Project for Statistical Computing.
Aurilio G, Mauri G, Rossi D et al. Image‐guided ablations in patients with recurrent renal cell carcinoma. J Clin Med 2023; 12: 4902
Hegarty NJ, Gill IS, Desai MM, Remer EM, O'Malley CM, Kaouk JH. Probe‐ablative nephron‐sparing surgery: cryoablation versus radiofrequency ablation. Urology 2006; 68(1 SUPPL): 7–13
Laeseke PF, Lee FT, Sampson LA, van der Weide DW, Brace CL. Microwave ablation versus radiofrequency ablation in the kidney: high‐power triaxial antennas create larger ablation zones than similarly sized internally cooled electrodes. J Vasc Interv Radiol 2009; 20: 1224–1229
Chan VW‐S, Abul A, Osman FH et al. Ablative therapies versus partial nephrectomy for small renal masses – a systematic review and meta‐analysis. Int J Surg 2022; 97: 106194
Salagierski M, Wojciechowska A, Zając K et al. The role of ablation and minimally invasive techniques in the management of small renal masses. Eur Urol Oncol 2018; 1: 395–402
John JB, Anderson M, Dutton T et al. Percutaneous microwave ablation of renal masses in a UK cohort. BJU Int 2021; 127: 486–494
Wilcox Vanden Berg RN, Calderon LP, LaRussa S et al. Microwave ablation of cT1a renal cell carcinoma: oncologic and functional outcomes at a single center. Clin Imaging 2021; 76: 199–204
Mershon JP, Tuong MN, Schenkman NS. Thermal ablation of the small renal mass: a critical analysis of current literature. Minerva Urol Nefrol 2020; 72: 123–134
Aarts BM, Gomez FM, Lopez‐Yurda M et al. Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis. Eur Radiol 2023; 33: 1040–1049
Abboud SE, Patel T, Soriano S, Giesler J, Alvarado N, Kang P. Long‐term clinical outcomes following radiofrequency and microwave ablation of renal cell carcinoma at a single VA medical center. Curr Probl Diagn Radiol 2018; 47: 98–102
Puza CJ, Wang Q, Kim CY. Evaluation of the heat sink effect after transarterial embolization when performed in combination with thermal ablation of the liver in a rabbit model. Cardiovasc Intervent Radiol 2018; 41: 1773–1778
Vogl TJ, Nour‐Eldin NEA, Hammerstingl RM, Panahi B, Naguib NNN. Microwave ablation (MWA): basics, technique and results in primary and metastatic liver neoplasms ‐ review article. Rofo 2017; 189: 1055–1066
Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol 2009; 38: 135–143
Simon CJ, Dupuy DE, Mayo‐Smith WW. Microwave ablation: principles and applications. Radiographics 2005; 25(suppl_1): S69–S83
Zhou W, Arellano RS. Thermal ablation of T1c renal cell carcinoma: a comparative assessment of technical performance, procedural outcome, and safety of microwave ablation, radiofrequency ablation, and cryoablation. J Vasc Interv Radiol 2018; 29: 943–951
Zhou W, Herwald SE, McCarthy C, Uppot RN, Arellano RS. Radiofrequency ablation, cryoablation, and microwave ablation for T1a renal cell carcinoma: a comparative evaluation of therapeutic and renal function outcomes. J Vasc Interv Radiol 2019; 30: 1035–1042
De Cobelli F, Papa M, Panzeri M et al. Percutaneous microwave ablation versus cryoablation in the treatment of T1a renal tumors. Cardiovasc Intervent Radiol 2020; 43: 76–83
Lucignani G, Rizzo M, Ierardi AM et al. Percutaneous microwave ablation is comparable to cryoablation for the treatment of T1a renal masses: results from a cross‐sectional study. Clin Genitourin Cancer 2022; 20: e506–e511
Castellana R, Natrella M, Fanelli G et al. Efficacy and safety of MWA versus RFA and CA for renal tumors: a systematic review and meta‐analysis of comparison studies. Eur J Radiol 2023; 165: 110943
Dvorak P, Hoffmann P, Brodak M et al. Percutaneous radiofrequency and microwave ablation in the treatment of renal tumors – 10 years of experience. Wideochir Inne Tech Maloinwazyjne 2017; 12: 394–402